跳至主要内容
临床试验/CTRI/2009/091/000628
CTRI/2009/091/000628未知1/2 期

An open-label, randomized, 2-period, cross-over study to determine the relative bioavailability of AEB071 from a coated tablet versus a capsule in healthy subjects

Novartis Healthcare Private Limited1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 待定

试验速览

阶段
1/2 期
入组人数
16
试验地点
1
主要终点
To determine the relative bioavailability of AEB071 from a coated tablet versus an immediate-release capsule

研究概览

简要总结

An open-label, randomized, 2-period, cross-over study to determine the relative bioavailability of AEB071 from a tablet formulation versus a capsule formulation in healthy subjects. Results will be used to guide formulation development decisions.

研究设计

分配方式
Computer generated randomization
盲法
Open Label

入排标准

入选标准

  • Health volunteers of either gender between 18 to 45 years.Women should be postmenopausal or surgically sterializedMales should be using contraception.

排除标准

  • SmokersHistory of any major illness, and abnormal lab assessmentThose who have intension to vaccine for 2 weeks or have had vaccine in the last 2 weeks.

结局指标

主要结局

To determine the relative bioavailability of AEB071 from a coated tablet versus an immediate-release capsule

时间窗: NIL

次要结局

  • To assess the safety and tolerability of AEB071 after single-dose administrations(NIL)

研究者

研究点 (1)

Loading locations...

相似试验